Great Basin Scientific Inc (NASDAQ:GBSN), a molecular diagnostics company, has appointed Suzette Chance, Ph.D. to serve as senior director of clinical affairs. In her role, Dr. Chance will lead clinical trial strategy and execution for Great Basin’s diagnostic products, beginning with upcoming trials for: Candida Blood Infections Panel; SA Nasal Screen Test; CT/NG Test; Stool Bacterial Pathogens Panel; and Pertussis/Parapertussis Test. All five trials are slated to begin in 2016 with expected clearance timeframes throughout 2017.

Dr. Chance has more than 20 years of experience in the in vitro diagnostics industry, and has a proven record of success taking product ideas from concept through commercialization, including clinical trials and U.S. Food & Drug Administration (FDA) clearance. Most recently, Dr. Chance served as senior director of research and development at Immucor GTI Diagnostics in Waukesha, Wis., where she specialized in transplantation and transfusion medicine. Prior to that, she served in R&D roles with Gen-Prob/Hologic and Genetic Testing Institute. Dr. Chance began her career as a scientist and biochemist with DuPont Medical Products in Glasgow, Del., where she created and established a new bio-analytical laboratory for the DuPont facility. She earned her B.S. degree in biochemistry at the University of Minnesota, her Ph.D. in biochemistry at Johns Hopkins University; School of Hygiene and Public Health, and completed a post-doctoral fellowship at Johns Hopkins University, School of Medicine, Department of Cell Biology and Anatomy. Dr. Chance has successfully shepherded more than 22 new products through the development and regulatory process in her career.

“Great Basin is committed to a very aggressive schedule for delivering new tests and panels that meet the needs of our current customers and spur adoption of Great Basin’s easy-to-use and cost-effective solution in new hospitals and labs,” said Robert D. Jenison, chief technology officer, Great Basin Scientific. “Suzette’s experience and leadership will be key to our ability to successfully deliver on our menu goals of nine cleared assays in 2017, and 16 to 17 assays in 2018. We are thrilled to welcome someone as knowledgeable and successful as Suzette to help us refine and expedite our clinical trial and FDA 510(K) submission processes as we embark on this exciting time of growth.” (Original Source)

Shares of Great Basin Scientific closed yesterday at $3.19, down $-0.06 or -1.85%. GBSN has a 1-year high of $10164 and a 1-year low of $2.52. The stock’s 50-day moving average is $4.86 and its 200-day moving average is $72.27.

Great Basin Scientific, Inc. develops and manufactures test kits and analyzers for a patented molecular diagnostic system used in single pathogen tests. The company provides a medical diagnostic test for the detection of Clostridium difficile, a gram-positive bacteria that causes diarrhea and other intestinal disorders. Great Basin Scientific was founded by David C. Ward, Anthony R. Torres and David Spafford on June 27, 2003 and is headquartered in Salt Lake City, UT.